News

HIV, lenacapavir

WHO recommends lenacapavir as twice yearly injection to help prevent HIV
Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a twice-yearly injectable.
Lenacapavir Offers Hope Against HIV, Now the World Must Act
A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.Presented at the International AIDS Society (IAS) Conference in Kigali,
WHO Endorses Injectable Lenacapavir As ‘Game-Changer’ In Global HIV Prevention Strategy
WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and low-resource settings, marking a major step in fighting global HIV spread.
WHO Backs Twice-Yearly Lenacapavir Injection for HIV Prevention
WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.
HIV prevention drug Lenacapavir recommended by WHO
Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this bi-annual injection could make in the fight against HIV.
WHO Endorses Lenacapavir for Twice-Yearly HIV Prevention in Landmark Update
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to daily oral regimens or shorter-acting injectables.
WHO releases new guidelines on injectable drug for HIV prevention
The World Health Organization has released new guidelines which, for the first time, recommend the use of an injectable form of pre-exposure prophylaxis (PrEP) for HIV prevention.
AARP20h
What Older Adults Need to Know About a New HIV Medication
Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...
Guyana Chronicle3h
WHO urges rollout of first long-acting HIV prevention jab
A BREAKTHROUGH HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...
WHO recommends twice-a-year HIV prevention shot as concern looms over funding for global HIV fight
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...
Managed Healthcare Executive2d
Lenacapavir’s Next Step: Turning Approval Into Access | IAS 2025
The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...
Lisa Jarvis: When an HIV scientific breakthrough isn’t enough
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
Applied Clinical Trials Online19h
Gilead’s Yeztugo Demonstrates Strong HIV Prevention Results in Underserved Populations
Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...
Managed Healthcare Executive3d
WHO Adds Lenacapavir to Its HIV PrEP Recommendations Amid Underutilization of PrEP and Severe PEPFAR Funding Cutbacks | IAS 2025
As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...